9 research outputs found

    The development of a composite sustainable development indicator for a corporate retail enterprise

    Get PDF
    Includes bibliographical references (leaves 134-145).This dissertation proposes a conceptual and methodological framework for the creation and implementation of a Composite Sustainable Development Indicator for a retail corporate entity. It provides a review and evaluation of existing approaches to sustainability development, and in particular Corporate Sustainability. The study selects and combines aspects of existing conceptual frameworks into a new conceptual framework for a Composite Sustainable Development Indicator for the retail context. It then applies this framework and general principles and criteria of sustainability assessment, in the selection and adaptation of an existing CSDI framework, namely the Barometer of Sustainability. An illustrative example of the application of the proposed methodological framework is also provided. The study was initiated based on the need for more research into the complexity of Composite Sustainability Indicators. The study also attempts to address the lack of effective methodologies for assessing, measuring and managing sustainability within a corporate environment. It thus proposes a more rigorous approach to sustainability that may enhance the current culture of reporting

    Beyond Assessment: Assuring Student Learning in Higher Education.

    No full text
    Setting up an 'Assurance of Learning' (AoL) system in line with requirements for accreditation is generally perceived to be a challenging task in both theory and practice. This paper provides an overview of the AoL system developed by the Faculty of Commerce and Administration to meet the requirements for accreditation by the Association to Advance Collegiate Schools of Business (AACSB), and describes its rationale, results achieved to date, and current challenges. The Faculty's system draws on the use of graduate attributes (Barrie, 2004), constructive alignment (Biggs, 1999), quality systems (Deming, 1982) and Theory of Constraints (Goldratt, 1994). In particular, individual student assessment is used to provide programme-level assurance of learning of graduate attributes. AoL's focus on 'closing the loop' – using student cohort performance data to inform system level change so that more students achieve the overall programme-level learning goals – is illustrated through a number of examples. While AoL developments have been led largely by business schools, we argue that wider adoption would allow universities to back up their claims about their students' achievement of graduate attributes, moving towards assuring, not just assessing, student learning

    The development of a composite sustainable development indicator for a corporate retail enterprise

    Get PDF
    Includes bibliographical references (leaves 134-145).This dissertation proposes a conceptual and methodological framework for the creation and implementation of a Composite Sustainable Development Indicator for a retail corporate entity. It provides a review and evaluation of existing approaches to sustainability development, and in particular Corporate Sustainability. The study selects and combines aspects of existing conceptual frameworks into a new conceptual framework for a Composite Sustainable Development Indicator for the retail context. It then applies this framework and general principles and criteria of sustainability assessment, in the selection and adaptation of an existing CSDI framework, namely the Barometer of Sustainability. An illustrative example of the application of the proposed methodological framework is also provided. The study was initiated based on the need for more research into the complexity of Composite Sustainability Indicators. The study also attempts to address the lack of effective methodologies for assessing, measuring and managing sustainability within a corporate environment. It thus proposes a more rigorous approach to sustainability that may enhance the current culture of reporting

    Brainstem Monitoring in the Neurocritical Care Unit: A Rationale for Real-Time, Automated Neurophysiological Monitoring

    No full text

    Vorapaxar in the secondary prevention of atherothrombotic events

    Get PDF
    Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)
    corecore